Evaluation of the post-antibiotic effect in vivo for the combination of a β-lactam antibiotic and a β-lactamase inhibitor: ceftazidime-avibactam in neutropenic mouse thigh and lung infections

References

• Eagle H, Musselman AD. The slow recovery of bacteria from the toxic effects of penicillin. J Bacteriol. 1949;58(4):475–90.
   PubMed Web of Science ®Google Scholar
• Eagle H. The effect of the size of the inoculum and the age of the infection on the curative dose of penicillin in experimental infections with streptococci, pneumococci, and Treponema pallidum. J Exp Med. 1949;90(6):595–607.
   PubMed Web of Science ®Google Scholar
• Craig WA. Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man. J Antimicrob Chemother. 1993;31 Suppl D:149–58.
   PubMed Web of Science ®Google Scholar
• Thorburn CE, Molesworth SJ, Sutherland R, Rittenhouse S. Postantibiotic and post-beta-lactamase inhibitor effects of amoxicillin plus clavulanate. Antimicrob Agents Chemother. 1996;40(12):2796–801.
   PubMed Web of Science ®Google Scholar
• Endimiani A, Hujer KM, Hujer AM, Pulse ME, Weiss WJ, Bonomo RA. Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2011;55(1):82–5.
   PubMed Web of Science ®Google Scholar
• Levasseur P, Girard AM, Lavallade L, Miossec C, Pace J, Coleman K. Efficacy of a ceftazidime-avibactam combination in a murine model of septicemia caused by Enterobacteriaceae species producing AmpC or extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 2014;58(11):6490–5.
   PubMed Web of Science ®Google Scholar
• Crandon JL, Schuck VJ, Banevicius MA, Beaudoin M-E, Nichols WW, Tanudra MA, Nicolau DP. Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2012;56(12):6137–46.
   PubMed Web of Science ®Google Scholar
• Berkhout J, Melchers MJ, van Mil AC, Seyedmousavi S, Lagarde CM, Schuck VJ, Nichols WW, Mouton JW. Pharmacodynamics of ceftazidime and avibactam in neutropenic mice with thigh or lung infection. Antimicrob Agents Chemother. 2016;60(1):368–75.
   PubMed Web of Science ®Google Scholar
• Pillar CM, Stoneburner A, Shinabarger DL, Krause KM, Nichols WW. The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria. Lett Appl Microbiol. 2016;63(2):96–102.
   PubMed Web of Science ®Google Scholar
• Berkhout J, Melchers MJ, van Mil AC, Nichols WW, Mouton JW. In vitro activity of ceftazidime-avibactam combination in in vitro checkerboard assays . Antimicrob Agents Chemother. 2015;59(2):1138–44.
   PubMed Web of Science ®Google Scholar
• Housman ST, Crandon JL, Nichols WW, Nicolau DP. Efficacies of ceftazidime-avibactam and ceftazidime against Pseudomonas aeruginosa in a murine lung infection model. Antimicrob Agents Chemother. 2014;58(3):1365–71.
   PubMed Web of Science ®Google Scholar
• Lahiri SD, Walkup GK, Whiteaker JD, Palmer T, McCormack K, Tanudra MA, et al. Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC. J Antimicrob Chemother. 2015;70(6):1650–8.
   PubMed Web of Science ®Google Scholar
• Pillar CM, Stoneburner A, Shinabarger DL, Krause KM, Nichols WW. Post-antibiotic effect (PAE) and post-beta-lactamase inhibitor effect (PLIE) of ceftazidime, ceftaroline, and aztreonam alone and in combination with avibactam against target Gram-negative organisms with extended-spectrum beta-lactamases. Poster P1734 presented at the 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 2014 May 10–13; Barcelona, Spain.
   Google Scholar
• Sy SKB, Zhuang L, Xia H, Beaudoin M-E, Schuck VJ, Nichols WW, Derendorf H. A mathematical model-based analysis of the time-kill kinetics of ceftazidime/avibactam against Pseudomonas aeruginosa. J Antimicrob Chemother. 2018;73(5):1295–304.
   PubMed Web of Science ®Google Scholar
• International Organization for Standardization. Clinical laboratory testing and in vitro diagnostic test systems - susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices, Part 1: reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases. ISO 20776-1:2006. Geneva, Switzerland: International Standards Organisation.
   Google Scholar
• Berkhout J, Melchers MJ, van Mil AC, Seyedmousavi S, Lagarde CM, Nichols WW, Mouton JW. Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice. Antimicrob Agents Chemother. 2015;59(4):2299–304.
   PubMed Web of Science ®Google Scholar
• Gudmundsson S, Einarsson S, Erlendsdottir H, Moffat J, Bayer W, Craig WA. The post-antibiotic effect of antimicrobial combinations in a neutropenic murine thigh infection model. J Antimicrob Chemother. 1993;31 Suppl D:177–91.
   PubMed Web of Science ®Google Scholar
• Vogelman B, Gudmundsson S, Turnidge J, Leggett J, Craig WA. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis. 1988;157(2):287–98.
   PubMed Web of Science ®Google Scholar
• Nichols WW, Newell P, Critchley IA, Riccobene T, Das S. Avibactam pharmacokinetic/pharmacodynamic targets. Antimicrob Agents Chemother. 2018;62(6):e02446-17.
   PubMed Web of Science ®Google Scholar
• Buijs J, Dofferhoff AS, Mouton JW, Wagenvoort JH, van der Meer JW. Concentration-dependency of beta-lactam-induced filament formation in Gram-negative bacteria. Clin Microbiol Infect. 2008;14(4):344–9.
   PubMed Web of Science ®Google Scholar
• Das S, Li J, Riccobene T, Carrothers TJ, Newell P, Melnick D, Critchley IA, Stone GG, Nichols WW. Dose selection and validation for ceftazidime-avibactam in adults with complicated intra-abdominal infections, complicated urinary tract infections, and nosocomial pneumonia. Antimicrob Agents Chemother. 2019;63(4):e02187–18.
   PubMed Web of Science ®Google Scholar
• Das S, Zhou D, Nichols WW, Townsend A, Newell P, Li J. Selecting the dosage of ceftazidime-avibactam in the perfect storm of nosocomial pneumonia. Eur J Clin Pharmacol. 2020;76(3):349–61.
   PubMed Web of Science ®Google Scholar
• Nichols WW, Stone GG, Newell P, Broadhurst H, Wardman A, MacPherson M, et al. Ceftazidime-avibactam susceptibility breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2018;62(11):e02590-17.
   PubMed Web of Science ®Google Scholar
• Keepers TR, Gomez M, Celeri C, Nichols WW, Krause KM. Bactericidal activity, absence of serum effect, and time-kill kinetics of ceftazidime-avibactam against β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2014;58(9):5297–305.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Zavicefta summary of product characteristics; 2016 [cited 2021 Jan 2]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004027/WC500210234.pdf.
   Google Scholar
• Singh R, Kim A, Tanudra MA, Harris JJ, McLaughlin RE, Patey S, O'Donnell JP, Bradford PA, Eakin AE. Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam. J Antimicrob Chemother. 2015;70(9):2618–26.
   PubMed Web of Science ®Google Scholar